The effects of Sitagliptin on the serum and ovarian inflammatory mediators of rats with polycystic ovary syndrome

Background: Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects 5-10% of women at reproductive age. Agents that improve metabolic syndrome have been useful for reducing PCOS complications. Since, the utilization of the drugs that improve metabolic syndrome and insulin resistance has clinical significance in control of PCOS and this syndrome is associated with low grade inflammatory state in the ovary, we designed this study to evaluate sitagliptin effects, as an inhibitor of DPP-4, on inflammatory biomarkers in ovary of PCOS rats.Objective: Recently, dipeptidyl peptidase 4 (DPP-4) inhibitors that block degradation of GLP-1used to treat PCOS. We designed this study to evaluate sitagliptin effects, as an inhibitor of DPP-4, on inflammatory biomarkers changes in ovary of PCOS rats.Materials and Methods: This research work is an interventional experimental study. After induction of the syndrome by single injection of estradiol valerate at dose of 4 mg/rat, PCO rats were divided into 3 groups including the PCOS, and the sitagliptin groups receiving daily administration of siagliptin at a dose of 25 or 50 mg/kg (P.O.) for 30 days. Thereafter, animal ovaries were removed for histological study and gene expression analysis. Blood samples were taken to evaluate serum TNF-α and CRP level. To evaluate the mRNA expression of the inflammatory mediatores (IL-6, TNF-α) after total RNA extraction. cDNA synthezied and Real time-PCR was performed. Serum levels of TNF-α and CRP were measured according to according to manufacturer kit instructions.Results: Treatment with sitagliptin significantly reduced the mRNA expression of IL-6 and TNF-α in the ovary. Serum levels of CRP and TNF-α were reduced in sitagliptin treated rats (p˂0.05).Conclusion: Generally, the results of this study showed that sitagliptin can improve the conditions of polycystic ovaries syndrome. In addition, the results indicate that part of the improvement effects of sitagliptin can be mediated by reducing serum and ovarian inflammatory markers.

Keywords:

PCOS , Sitagliptin , Inflammatory , Rat